Evidence map›Paper›PMID 27721792›Full record

ArticleFrontiers in pharmacology2016

An NBD Derivative of the Selective Rat Toxicant Norbormide as a New Probe for Living Cell Imaging.

Claudio D'Amore, Genny Orso, Fabio Fusi, Mario A Pagano, Giovanni Miotto, Alessia Forgiarini, Sara De Martin, Giulia Castellani, Giovanni Ribaudo, David Rennison and 4 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Cells · 2021
    Article
  4. Article
  5. Review
  6. Naringenin AmelioratesFrontiers in neuroscience · 2019
    Article
  7. The Selective Rat Toxicant Norbormide Blocks KFrontiers in pharmacology · 2019
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 2 countries.

Claudio D'AmoreDepartment of Surgical and Biomedical Sciences, University of Perugia Perugia, Italy.
Genny OrsoIRCCS "E. Medea" Conegliano, Italy.
Fabio FusiDepartment of Life Sciences, University of Siena Siena, Italy.
Mario A PaganoDepartment of Pharmaceutical and Pharmacological Sciences, University of Padua Padua, Italy.
Giovanni MiottoDepartment of Molecular Medicine, University of Padua Padua, Italy.
Alessia ForgiariniIstituto di Ricerca Pediatrica Città della Speranza Padua, Italy.
Sara De MartinDepartment of Pharmaceutical and Pharmacological Sciences, University of Padua Padua, Italy.
Giulia CastellaniDepartment of Pharmaceutical and Pharmacological Sciences, University of Padua Padua, Italy.
Giovanni RibaudoDepartment of Pharmaceutical and Pharmacological Sciences, University of Padua Padua, Italy.
David RennisonSchool of Chemical Sciences, University of Auckland Auckland, New Zealand.
Margaret A BrimbleSchool of Chemical Sciences, University of Auckland Auckland, New Zealand.
Brian HopkinsSchool of Chemical Sciences, University of AucklandAuckland, New Zealand; Landcare ResearchLincoln, New Zealand.
Alessandro FerrareseDepartment of Pharmaceutical and Pharmacological Sciences, University of Padua Padua, Italy.
Sergio BovaDepartment of Pharmaceutical and Pharmacological Sciences, University of Padua Padua, Italy.
University of Padua · ITUniversity of Auckland · NZCittà della Speranza Foundation · ITIRCCS Eugenio Medea · ITManaaki Whenua – Landcare Research · NZUniversity of Perugia · ITUniversity of Siena · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Norbormide (NRB) is a unique compound that acts directly on rat vascular myocytes to trigger a contractile process, through an as yet unknown mechanism, which results in the selective contraction of rat peripheral arteries. To gain insight into the mechanisms involved in NRB rat-selective activity, we investigated the subcellular distribution of NRB-AF12, a nitrobenzoxadiazole (NBD)-derivative of NRB, in living NRB-sensitive and NRB-insensitive cells. In both cell types, NRB-AF12 localized to the endoplasmic reticulum (ER), Golgi apparatus, mitochondria, lysosomes, and endosomes; however, in NRB-sensitive cells, the fluorescence also extended to the plasma membrane. NRB-AF12 was rapidly internalized into the cells, could easily be washed out and then reloaded back into the same cells, all with a high degree of reproducibility. Cells exposed for 24 h to NRB-AF12 did not show apparent signs of toxicity, even at concentrations of the dye (10 μM) much higher than those required for fluorescence labeling (500 ηM). The distribution pattern of NRB-AF12 fluorescence was near identical to that of ER-Tracker® (Er-Tr), a fluorescent derivative of glibenclamide, a known K

Indexed as

ER trackerfluorescent probesLX2 cellsnorbormidesulphonylurea receptors

Identifiers

PMID27721792
PMCPMC5034647
OpenAlexW2521227953

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.